Marina Biotech, Inc. is a fully integrated, commercial stage biopharmaceutical company delivering proprietary drug therapeutics for significant unmet medical needs in the U.S., Europe and additional markets. Our portfolio of products focuses on fixed dose combinations FDC in hypertension, arthritis, pain and oncology allowing for innovative solutions to such unmet medical needs. Our approach is meant to reduce clinical risk and accelerate time to market by shortening the clinical development program through leveraging what is already known or can be learned in our proprietary Patient Level Database. We currently have one commercial and three clinical development programs underway: i Prestalia , a single pill FDC of perindopril and amlodipine, which has been approved by the FDA and is actively marketed in the U.S. ii our next generation celecoxib program drug candidates for the treatment of acute and chronic pain, IT and IT , each of which is an FDC of celecoxib and either lisinopril IT or olmesartan IT iii CEQ , an oral delivery of small interfering RNA against beta catenin, combined with IT to suppress polyps in the precancerous syndrome and orphan indication Familial Adenomatous Polyposis and iv CEQ combined with IT to treat Colorectal Cancer.
Quote | Moderna Inc. (NASDAQ:MRNA)
Last: | $129.06 |
---|---|
Change Percent: | 0.65% |
Open: | $127.49 |
Close: | $129.06 |
High: | $129.2 |
Low: | $124.98 |
Volume: | 2,941,740 |
Last Trade Date Time: | 05/15/2024 03:00:00 am |
News | Moderna Inc. (NASDAQ:MRNA)
2024-05-15 14:20:39 ET Summary This monthly article series shows aggregate industry metrics in the healthcare sector. All healthcare subsectors are overvalued based on my metrics. Pharmaceuticals/biotechnology has the lowest scores in both value and quality. Invesco S&P 50...
2024-05-15 12:19:13 ET Summary Moderna reported better-than-expected 1Q24 revenue of $167 million. The FDA's decision on Moderna's RSV vaccine has been delayed, adding uncertainty to its potential approval and market entry. Moderna's pipeline looks promising. I have a bull...
Message Board Posts | Moderna Inc. (NASDAQ:MRNA)
Subject | By | Source | When |
---|---|---|---|
Cathie Wood's ARK Innovation ETF buys shares of | axelvento | investorshub | 05/01/2023 4:39:04 AM |
Believe in what | Vexari | investorshub | 05/01/2023 4:25:38 AM |
the important thing is to believe not to hope! | axelvento | investorshub | 05/01/2023 4:14:06 AM |
The thought of overthinking without explanation | Vexari | investorshub | 04/30/2023 8:03:20 PM |
Without understanding | Vexari | investorshub | 04/29/2023 9:23:49 PM |
News, Short Squeeze, Breakout and More Instantly...
On CNBC's “Mad Money Lightning Round,” Jim Cramer believes in Moderna, Inc. (NASDAQ:MRNA). On May 14, Evercore ISI Group analyst C...
2024-05-14 06:35:00 ET Investors have put their hopes in Moderna 's (NASDAQ: MRNA) next potential product, a respiratory syncytial virus (RSV) vaccine. That's because it represents a new revenue stream for a company that until now has relied on just one product, and a product strugg...
Moderna (NASDAQ:MRNA) has outperformed the market over the past 5 years by 27.7% on an annualized basis producing an average annual return of 40.43...